Skip to content

GeneDx Holdings WGS Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale

Proceeds from Maturities, Prepayments and Calls of Debt Securities, Available-for-Sale at other companies

Personalis, Inc. logo
Personalis, Inc.PSNL
$24.1M-45.5%
Natera, Inc. logo
Natera, Inc.NTRA
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO

Other financials

Income statement

See full
Revenue$102.3M+17.4%
Gross profit$68.2M+16.6%
Operating income-$57.5M-1,163%
Net income-$63.3M-870%
EPS (diluted)-$2.16-839%

Balance sheet

See full
Cash & equivalents$94.9M-5.7%
Total debt$96.7M+82.5%
Total equity$254.1M-1.3%
Total assets$506.3M+13.4%

Cash flow

See full
Operating cash flow-$32.4M-418%
CapEx$6.5M+5.3%
Free cash flow-$38.9M-1,059%

Valuation

See full
Market cap$1.89B-24.3%
Enterprise value$1.89B-22.8%
P/S4.3×-3.3×

Profitability

See full
Gross margin69.6%+4.3pp
Operating margin-14.9%
Net margin-17.6%
FCF margin3.8%+2.1pp

Returns & leverage

See full
Return on equity-30.4%
Debt / equity0.4×+0.2×
Current ratio3.1×-0.2×

Where this comes from

Reported directly by GeneDx Holdings in its filing.

Tagged under the XBRL concept us-gaap:ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities.

The official record: GeneDx Holdings’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about GeneDx Holdings's proceeds from maturities, prepayments and calls of debt securities, available-for-sale.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is GeneDx Holdings's proceeds from maturities, prepayments and calls of debt securities, available-for-sale?
GeneDx Holdings (WGS) reported proceeds from maturities, prepayments and calls of debt securities, available-for-sale of $8.5M in Q1 2026.
How has GeneDx Holdings's proceeds from maturities, prepayments and calls of debt securities, available-for-sale changed year-over-year?
GeneDx Holdings's proceeds from maturities, prepayments and calls of debt securities, available-for-sale decreased by 39.0% year-over-year, from $13.93M to $8.5M.
What is the long-term trend for GeneDx Holdings's proceeds from maturities, prepayments and calls of debt securities, available-for-sale?
Over 2 years (2023 to 2025), GeneDx Holdings's proceeds from maturities, prepayments and calls of debt securities, available-for-sale has grown at a 57.3% compound annual growth rate (CAGR), from $17.77M to $43.97M.
What does proceeds from maturities, prepayments and calls of debt securities, available-for-sale mean?
This measures cash inflows resulting from the natural maturity or early redemption of debt securities held in the investment portfolio. It indicates the recurring cash generation from the company's fixed-income investment strategy.